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Summary Since the discovery of atrial natriuretic peptide (ANP), there has been tremendous
progress in our understanding of the physiologic and pathophysiologic, diagnostic, and ther-
apeutic roles of ANP. The diagnostic application of ANP and brain natriuretic peptide (BNP)Heart failure;
Heart failure
treatment;
Prognosis;
has been reviewed by many investigators, and meta-analyses of therapeutic use of BNP were
reported from the USA. However, there are few reviews concerning the therapeutic use of ANP
in patients with various conditions. Therefore, this review focuses on the recent clinical evi-
dence of ANP in therapeutic use and experimental data that rationally support the therapeutic
use of ANP.Renal function
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the cGKI/myosin light chain phosphatase (MLCP) signal-
ing pathway. cGKI/IRAG signaling inhibits release of Ca++
from sarcoplasmic reticulum (SR) cGKI binds, phosphory-
lates, and activates RGS2, which terminates signaling by
Gq-coupled receptors for contractile agonists [16]. There-
Table 1 Biological actions of atrial and brain natriuretic
peptides.
Diuresis
Natriureis
Hypotensive action
Inhibition of aldosterone secretion
Anti-hypertrophic action
Anti-ﬁbrotic action
Inhibition of cell proliferation
Smooth muscle cell
Mesangial cellReferences ...............................................
Introduction
Since the discovery of atrial natriuretic peptide (ANP) at
the end of 1983 [1] and the beginning of 1984 [2], major
advances have taken place in our understanding of the physi-
ology and pathophysiology of the heart. Before the discovery
of ANP, the heart was believed to function solely for the
delivery of blood to all organs in the body; after ANP was
elucidated, it became evident that the heart also regulates
blood pressure, ﬂuid volume, and electrolyte balance [3,4].
Therefore, the heart plays at least two major biological
roles: a pumping function and an endocrine function.
During the past three decades, evidence accumulated
that a number of hormones, paracrine factors, and intracel-
lular signaling molecules are involved in heart development,
cardiac contraction, cardiac hypertrophy, and heart failure
(HF). Among these biologically active substances, ANP and
B-type natriuretic peptide (BNP) are the best-investigated
molecules, and are now clinically used as diagnostic tools
and therapeutic drugs in HF.
In 1995, the Ministry of Health and Welfare of Japan
approved recombinant ANP (carperitide) for intravenous
administration in patients with acute heart failure (AHF) and
acutely decompensated heart failure (ADHF). However, the
recombinant form of BNP (nesiritide) was not approved for
therapeutic use in Japan. In contrast, in the USA, the Food
and Drug Administration (FDA) approved nesiritide in 2001.
Therefore, the clinical evidence for ANP has been compiled
mainly in Japan, whereas the evidence for BNP is mainly
from the USA. Several reviews and meta-analyses concern-
ing BNP use were generated using data obtained in the USA
[5—7]. In this context, this review focuses on recent clin-
ical data regarding ANP as a therapeutic agent in several
diseases, as well as experimental data from genetically engi-
neered mice which may rationalize the clinical usefulness of
ANP.
Discovery of natriuretic peptide (NP) family
The discovery of atrial-speciﬁc granules, which resemble the
electron-dense granules observed in endocrine organs, by
Kirsh [8] in 1956 marks one of the ﬁrst milestones on the road
of ANP research. In 1979, deBold [9] found that the number
of atrial-speciﬁc granules is decreased by water deprivation
and increased by salt loading, suggesting that atrial-speciﬁc
granules contain a biologically active substance involved in
volume regulation. At the end of 1983 and the beginning
of 1984, a new peptide with 28 amino acid residues was
isolated by deBold from rat atrial tissues [1], and by Mat-
suo and Kangawa from human atrial tissues [2]. The peptide
was designated as ANP, and exhibits diuretic, natriuretic,.......................................................... 269
nd vasodilating activities. Following the discovery of ANP,
atsuo and Kangawa also isolated brain natriuretic peptide,
r B-type natriuretic peptide (BNP) from the porcine brain
n 1988 [10], and C-type natriuretic peptide (CNP) from the
orcine brain in 1990 [11]. ANP is mainly synthesized in the
tria and BNP in the ventricles; thus, ANP and BNP are car-
iac hormones [12—14]. The expression of ANP and BNP is
ncreased in cardiac hypertrophy in response to atrial or
entricular wall stress, respectively, as well as in HF. CNP
s synthesized in endothelial cells, macrophages, neurons,
nd osteoblasts, although cardiac expression of CNP is low
3,4].
iological actions of ANP and BNP
NP and BNP bind their common receptor, guanylyl cyclase-
(GC-A), which is a membrane-type guanylyl cyclase, and
eads to biological actions through a cGMP-dependent path-
ay (Table 1). Classically ANP and BNP possess diuretic,
atriuretic, and hypotensive activity. ANP induces dila-
ion of arteries and veins in an endothelium-independent
anner. In vascular smooth muscle cells (SMCs), GC-A is
xpressed abundantly; binding of ANP or BNP produces cGMP
nd activates cGMP-regulated protein kinase I (cGKI) [15].
MCs express both cGKI and cGKI· Earlier reports showed
hat cGKI inhibits vascular smooth muscle contraction by
ultiple mechanisms, including the cGKI/inositol 1,4,5-
riphosphate-associated cGMP kinase substrate (IRAG), the
GKI/regulator of G protein signaling subtype 2 (RGS2), andFibroblasts
Enhancement of permeability of macromolecules through
endothelium
Angiogenic action
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Table 2 Blood pressure proﬁle in tissue speciﬁc GC-A KO mice.
BP BP response to ANP Permeability response to ANP
Floxed GC-A → ↓ Yes
Straight GC-A KO ↑ → No
SMC-GC-A KO → → Not done
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GC-A, guanylyl cyclase-A; KO, knockout; BP, blood pressure; ANP,
cell.
ore, it is likely that cGKI/RGS2 signaling inhibits hormone
eceptor-triggered Ca2+ release and vasoconstriction. In
he cGKI/MLCP signaling pathway, cGKI activates MLCP.
ncreased MLCP activity reduces myosin light chain phos-
horylation and causes relaxation. Thus, these are the
echanisms of the acute depressor effect of ANP. However,
ecently Kuhn et al. [17] reported that the mechanisms of
he chronic depressor effect of ANP are quite different from
hose of the acute effect. The chronic depressor effect is
ue to a decrease in intravascular volume resulting from
ncreased permeation of water and macromolecules through
he endothelium into the interstitial space [17].
In the kidney, ANP increases the glomerular ﬁltration rate
GFR) due to an elevation of glomerular capillary hydrostatic
ressure that results from dilation of afferent arterioles
nd, in some cases, from slight constriction of efferent
rterioles. Thus, ANP has dose-dependent effects of solute
nd water excretion [18]. The natriuretic effect of ANP is
ttributed almost entirely to cGMP-dependent inhibition of
odium reabsorption in the inner medullary connecting duct
nd chloride in the cortical collecting duct. ANP appears to
oordinately inhibit apical sodium channels and the basolat-
ral Na+, K+-ATPase [18]. ANP also inhibits angiotensin II- or
opamine-induced sodium absorption in proximal tubules.
In addition to its vascular and renal function, ANP inhibits
ldosterone secretion from cultured adreno-cortical cells.
linically, when ANP is infused in healthy subjects and
atients with HF, the plasma aldosterone concentration
ecreases promptly and returns after cessation of infusion.
oles of ANP and BNP: lessons from
enetically engineered mice
oles of ANP and BNP in blood pressure and
ardiac remodeling
he physiological roles of ANP and BNP have been inves-
igated using ANP knockout (KO) mice [19] and GC-A KO
ice [20]. ANP KO mice exhibit salt-sensitive hypertension
19], but GC-A KO mice exhibit salt-insensitive hyperten-
ion with ventricular hypertrophy and ﬁbrosis [20]. The
eason for the phenotypic difference between ANP and
C-A KO mice remains unclear. Cardiac remodeling in GC-
KO mice is blood pressure-independent, and is almostompletely inhibited by crossing with AT1 KO mice or treat-
ent with angiotensin receptor blocker, suggesting that
he GC-A signaling functionally antagonizes the AT1 sig-
aling [21,22]. As mentioned above, cGKI binds directly
o and phosphorylates/activates RGS2, which terminates
v
c
e
rNo
l natriuretic peptide; SMC, smooth muscle cell; EC, endothelial
(q)-coupled receptor signaling in vascular smooth mus-
le [16]. Consistent with this, Tokudome et al. reported
hat cardiomyocyte-speciﬁc overexpression of RGS4, the
ajor RGS protein in the cardiomyocytes, in GC-A-KO
ice signiﬁcantly reduced hypertrophy, cardiomyocyte size,
nd ventricular calcineurin activity [23]. Thus, the pos-
ible mechanism for the antagonistic action of ANP and
NP against angiotensin II may be explained by GC-
/cGKI/RGS4 interaction. Treatment with an aldosterone
locker, eplerenone, signiﬁcantly improved ventricular
ypertrophy and ﬁbrosis [24]. Currently, it remains unclear
ow GC-A signaling interacts with other signaling pathways
ia a mineralocorticoid receptor.
The mechanism for hypertension in GC-A has been inten-
ively investigated by Kuhn et al. using SMC- [25] or
ndothelial cell-(EC) [17] speciﬁc GC-A KO mice (Table 2).
MC-speciﬁc GC-A KO (SMC-GC-A KO) mice exhibit blood
ressure equal to control mice (GC-Aﬂox/ﬂox), but have no
ypotensive response to exogenously administered ANP. In
C-speciﬁc GC-A KO (EC-GC-A KO), blood pressure is sim-
larly elevated to the level in straight GC-A KO mice,
ut exogenous ANP injection signiﬁcantly decreases blood
ressure. Kuhn et al. [26] also proved that ANP enhances
icrovascular endothelial macromolecule permeability in
ivo. These results clearly indicate that the mechanism
or hypertension in GC-A KO mice involves an increase in
ntravascular volume resulting from the inhibition of per-
eation of the blood from the intravascular space to the
xtravascular space. It remains unknown which channels or
ransporters are involved in GC-A-mediated permeation in
C.
oles of ANP and BNP in acute myocardial
nfarction
number of experimental and clinical studies revealed that
xpression of ANP and especially BNP are increased in the
nfarct region of the ventricle. Plasma levels of ANP and BNP
re also increased in the acute phase of acute myocardial
nfarction (AMI) in humans; plasma BNP increases espe-
ially rapidly, decreases within 24 h, increased again within 7
ays and then decreases gradually [27]. When patients are
reated with angiotensin-converting enzyme inhibitor, this
econd peak is obscured [28], suggesting that the second
ransient elevation of plasma BNP level is related to acute
entricular stress. Thus, ANP and BNP have some pathologi-
al roles in AMI as hormones and/or paracrine factors.
To investigate the roles of ANP and BNP in AMI, we gen-
rated permanent coronary occlusion models and ischemia
eperfusion models in GC-A KO mice and BNP transgenic
Roles of atrial natriuretic peptide and its therapeutic use 265
Figure 1 Survival curve and ventricular remodeling after permanent coronary ligation in guanylyl cyclase-A (GC-A) knockout (KO)
mice and double KO mice lacking both GC-A and type 1 angiotensin receptor genes. (A) Kaplan—Meier survival curve in GC-A KO
mice, GC-A KO mice with hydralazine treatment and double KO mice after permanent coronary ligation. (B) Collagen volume fraction
(%) in the ventricles 4 weeks after coronary ligation (right) and sham operated mice (left). Values are represented means± SEM.
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with von-Gieson-staining in four genotypes of mice. MI, myocar
Adapted from Nakanishi et al. [29].
(BNP-Tg) mice. When GC-A KO and wild-type (WT) mice
were subjected to permanent coronary ligation, the GC-
A KO mice exhibited lower survival rate and more severe
ventricular ﬁbrosis and post-infarct hypertrophy than WT
mice [29]. GC-A KO mice with AMI died within 7 days
after ligation; a major cause of death was probably HF,
because lung weight is signiﬁcantly heavier in GC-A KO mice.
Urine volume and urinary excretion of sodium decreased
just after the operation in both genotypes of mice; GC-
A KO mice recovered more slowly than WT mice, which
may be related to the more severe HF in GC-A KO mice.
Because GC-A KO mice are hypertensive, we investigated
whether or not hydralazine treatment rescues the poor sur-
vival rate and ventricular remodeling in GC-A KO mice;
however, this treatment rescued neither poor survival nor
ventricular remodeling. Given that the phenotype of GC-
A KO is almost blocked by crossing with mice lacking type
1 angiotensin receptor (AT1), we generated an AMI model
in GC-A and AT1 double KO mice. The results were very
interesting. Although chronic ventricular remodeling such as
hypertrophy and ﬁbrosis disappeared almost completely in
double KO mice (Fig. 1B and C), the survival rate in double
KO mice was the same as in GC-A KO mice (Fig. 1A) [29].
These ﬁndings suggest that chronic ventricular remodeling
is AT1-dependent, but acute death is not AT1 dependent.
o
a
p
s
l001 vs. GC-A KO. (C) Representative histological examination
nfarction; DKO, double knockout.
herapeutic application of ANP in the acute phase may
ave some beneﬁcial effects in AMI that cannot be replaced
y angiotensin receptor blockers or angiotensin-converting
nzyme inhibitors.
To determine whether GC-A signaling contributes to the
xtension of infarction in the very acute phase of AMI, we
eveloped a model involving 30-min coronary artery lig-
tion followed by 48-h reperfusion. Unexpectedly, infarct
ize assessed by triphenyltetrazolium chloride staining was
igniﬁcantly smaller in GC-A KO mice than WT mice. His-
ological examination revealed that neutrophils were less
nﬁltrated into the infarct region, with lower expression lev-
ls of P-selectin in coronary artery endothelium in GC-A KO
ice. P-selectin is involved in the inﬁltration of neutrophils,
nd plays key roles in reperfusion injury in myocardium; con-
istent with this, reperfusion injury is less severe in GC-A KO
ice. Moreover, we conﬁrmed that endothelial expression of
-selectin is transcriptionally promoted by NF-B activation
n which GC-A signaling is involved [30] (Fig. 2).
We also generated a permanent occlusion model in mice
verexpressing the BNP gene under control of the serum
myloid protein A promoter, in which mice BNP is not overex-
ressed in the heart but in the liver, and BNP is constitutively
ecreted from the liver, resulting in high circulating BNP
evel of ∼10 ng/ml. When AMI was generated in BNP-Tg
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Pigure 2 Event-free incidence for death and rehospitalizati
atient outcomes (bottom table).
eproduced from Hata et al. [43] with permission.
ice, BNP-Tg mice more frequently died ∼3 to 5 days
fter the occlusion due to ventricular free wall rupture,
ith more massive inﬁltration of neutrophils in the infarct
egion than WT mice. In BNP-Tg mice, higher expression
f metalloproteinase-9 (MMP-9) was observed in inﬁltrated
eutrophils by immunostaining and overactivation of MMP-
, and was conﬁrmed by gelatin-zymography. This result
uggests that activation of MMP-9 was related to the free
all rupture. BNP-Tg mice were rescued by treating with
oxycycline, an inhibitor of MMP-9 [31].
oles of ANP and BNP in renal diseases
o date, there has been no report describing the roles of
NP or BNP in kidney disease using genetic ablation mod-
ls. Renal abnormalities in GC-A KO mice and ANP KO mice
ave not been described in earlier reports. In fact, we
ound neither macroscopic nor microscopic abnormalities
n the kidney of GC-A KO mice, suggesting ANP/GC-A sig-
aling does not play important roles in the development of
he kidney. Endogenous expression levels of ANP and BNP
enes in the kidney are quite low compared with those
n the heart, whereas GC-A is abundantly expressed in
he kidney. Therefore, ANP and BNP systems act as hor-
ones rather than paracrine factors in the kidney. GC-A
O mice do not increase urination and sodium excretion
n response to volume overload with iso-osmotic solution
20].
Kasahara et al. [32] investigated the effect of high lev-
ls of circulating BNP on glomerular injury induced by
ubtotal nephrectomy (two-thirds right renal resection and
eft renal resection) using BNP-Tg mice. Subtotal nephrec-
omy induced mild to moderate systemic hypertension,
ncreased serum creatinine levels, and caused albuminuria
ogether with remarkable glomerular hypertrophy and mod-
rate mesangial expansion 16 weeks after operation in WT
ice, relative to sham-operated mice. However, in BNP-Tg
ice all these ﬁndings were lessened signiﬁcantly. Although
lomerular expression of transforming growth factor- and
bronectin was also increased after subtotal nephrectomy
s
w
g
r
gpatients with acute myocardial infarction (upper ﬁgure) and
n WT mice, the expression was less increased in BNP-Tg
ice. The renal-protective effect of circulating BNP follow-
ng glomerular injury was also reported for anti-glomerular
asement membrane nephritis [33] and diabetic nephropa-
hy [34].
oles of ANP in angiogenesis
ecently, a new function for the NP/GC-A system—–as reg-
lator of angiogenesis of heart and skeletal muscle—–was
eported by two groups independently [35,36]. Vascular
egeneration in response to hind limb ischemia was severely
mpaired in GC-A KO mice. EC-GC-A KO mice exhibited
imilar responses, but SMC-GC-A KO mice did not affect
schemic neovascularization. Bone marrow transplantation
xperiments showed that GC-A signaling did not inﬂuence
obilization of vascular progenitor cells from bone mar-
ow. BNP expression was augmented in satellite cells within
schemic skeletal muscle, suggesting that local BNP elic-
ts protective endothelial effects. Yamahara et al. [37]
eported that neovascularization in response to hind-limb
schemia was more accelerated in BNP-Tg mice than in WT
ice. These ﬁndings suggest the possibility that ANP is a
otentially valuable therapeutic agent for stimulating angio-
enesis in ischemic tissues.
herapeutic use of ANP for heart diseases
reclinical reports of ANP infusion
iven that ANP possesses diuretic, natriuretic, and vasodi-
ating activities, cardiologists have hypothesized since its
iscovery that ANP might be useful for the treatment of HF.
reclinical investigations concerning the effect of ANP infu-
ion in cardiac, renal, and hormonal functions in patients
ith congestive HF were reported in 1986 and 1987 by three
roups of investigators, including us [38—40]. Although the
eports were of small studies, the results from all three
roups were similar and signiﬁcant. In our report, ANP
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infusion at a rate of 0.1g/kg/min signiﬁcantly decreased
pulmonary capillary wedge pressure and systemic vascular
resistance, and increased stroke volume index. Thus, ANP
improves cardiac function by altering loading conditions for
the left ventricle. ANP infusion increases GFR and induces
diuresis. A signiﬁcant reduction in plasma levels of aldos-
terone was observed. Based on the preclinical data, ANP
was licensed in Japan in 1995 for the treatment of AHF or
ADHF. Japan was the ﬁrst country in the world to approve the
drug for this use. Today, ANP is commonly used in patients
with AHF and ADHF, and its market share is the largest in
the AHF and ADHF market. The total cost of ANP in 2009 in
Japan was over 10 billion yen.
Therapeutic use of carperitide for HF
Both before and after the clinical launch of carperitide in
Japan, there has been no large-scale randomized double-
blind study to conﬁrm whether or not carperitide infusion
improves cardiac function, clinical symptoms, and progno-
sis in patients with AHF or ADHF. However, two large-scale
prospective open-label observational studies have been
reported [41,42]. One observational study was conducted as
a post-marketing surveillance study, in order to observe the
efﬁcacy and safety of carperitide. This study enrolled 3777
patients with AHF, who were administered carperitide at a
median dosage of 0.085g/kg/min for a median duration
of 65 h. During the infusion, 82% of the patients were clini-
cally improved. The incidence of adverse events was 16.9%,
most frequent being hypotension (9.5%), which occurred in
the ﬁrst 3 h of infusion, with 96% of patients recovering or
improving without speciﬁc treatment [41]. Another obser-
vational study was Carperitide Effects Observed Through
Monitoring Dyspnea in Acute Decompensated Heart Failure
Study (COMPASS) [42]. COMPASS was conducted to evalu-
ate the efﬁcacy and safety of carperitide monotherapy in
patients with AHF or ADHF; 1832 patients were enrolled.
Prior to or in addition to carperitide P infusion, bolus
injection of diuretic, nitrates, and digoxin was permitted.
Carperitide was administered at an initial dose of less than
0.05g/kg/min in 82.2% of patients, and mean duration
of the infusion was 5.2± 4.8 days. Improvement of sub-
jective symptoms was evaluated by modiﬁed Borg scale;
symptoms signiﬁcantly declined within 2 h after the infusion.
In 1524 patients (83.2%), carperitide infusion was stopped
because of HF-related symptoms and signs, and was suc-
cessfully replaced with standard oral agents for chronic HF.
Adverse effects were observed in only 4.64% of the patients;
the most frequently reported was hypotension, in 3.55%.
Looking beyond the acute effect of carperitide on relief of
symptoms, another study, PROTECT, investigated the effect
of carperitide on the long-term prognosis of AHF [43]. The
PROTECT study enrolled 49 patients with anterior ADHF who
were randomly assigned into a group receiving low-dose
carperitide (0.01—0.05g/kg/min) for 72 h and a group that
received standard medical treatment. During the infusion,
the cardiac free fatty acid-binding protein/serum creati-
nine ratio was reduced, suggesting inhibition of myocardial
cell membrane damage. There was no signiﬁcant differ-
ence in serum troponin T and creatinine levels between
the two groups of patients. During an 18-month follow-up,
s
M
A
c267
ncidence of death and rehospitalization was signiﬁcantly
ower in the carperitide group than in the control group.
hus, acute-phase transient low-dose ANP infusion improves
he long-term prognosis in patients with ADHF. Although the
echanism for long-term beneﬁcial effect of ANP is not clear
t present, inhibition of the renin-angiotensin-aldosterone
ystem [44] and/or anti-oxidant [45] effect of low-dose of
NP infusion may be involved in the mechanism.
herapeutic use of ANP for AMI
iven that GC-A mice with permanent coronary artery lig-
tion showed worse ventricular remodeling and prognosis
han WT mice [29], ANP infusion has been hypothe-
ized to improve prognosis in patients with AMI. Hayashi
t al. [46] enrolled 60 patients with AMI who under-
ent emergent coronary intervention. After successful
ecanalization, 30 patients were randomly assigned into
he ANP group (0.025g/kg/min of carperitide) and 30
atients into the nitroglycerin group 0.4g/kg/min. Carper-
tide or nitroglycerin treatment lasted for more than
4 h, and was then replaced with oral inhibitors of the
enin—angiotensin—aldosterone system in both groups of
atients. At the end of the infusion, plasma angiotensin II,
ldosterone, and endothelin levels were lower in the ANP
roup. Although the baseline hemodynamics and left ven-
ricular function were similar in both groups, 1 month after
nset the left ventricular end-diastolic volume index was
igniﬁcantly lower, and ejection fraction was signiﬁcantly
igher in the ANP group than the control group, indicating
hat ANP infusion improves left ventricular remodeling after
MI. To conﬁrm this scenario in a larger population, Kitakaze
t al. [47] conducted the J-WIND study, which is a multicen-
er prospective randomized single-blind study to evaluate
fﬁcacy of ANP infusion in the acute phase in patients with
MI, who received percutaneous coronary intervention. In
he J-WIND study, 277 patients were assigned to the ANP
roup who received low-dose carperitide (0.025g/kg/min)
or 72 h, and 292 to the control group, who received the
ame dose of vehicle. The primary endpoints were the
nfarct size, assessed as the area under the concentration
ersus time curve for creatine kinase; and ejection fraction
n the chronic phase (6—12 months after the onset), assessed
y left ventriculography. Infarction size was signiﬁcantly
ecreased by ∼15% in the ANP group (p < 0.016), and ejec-
ion fraction was signiﬁcantly higher (p < 0.024). Incidence
f cardiac death and HF, taken as secondary endpoints, was
igniﬁcantly lower in the ANP group. These studies indicate
hat ANP treatment is an effective adjunctive therapy in
atients with AMI (Fig. 3).
herapeutic application of ANP in renal
iseases
ffect of ANP in renal function during cardiac
urgery
ore than 25 years have passed since the discovery of
NP, but there have been no case reports of ANP deﬁ-
iency. However, during cardiopulmonary bypass in cardiac
2 Y. Saito
s
l
h
B
r
m
u
w
t
w
o
t
n
d
c
a
d
i
s
t
P
n
R
d
i
i
F
e
R
F
R
a
R
c68
urgery, the plasma ANP level decreased to an undetectable
evel. Because ANP and BNP are solely secreted from the
eart, cardiopulmonary bypass artiﬁcially creates ANP and
NP deﬁciency. Sezai et al. [48] investigated the effect on
enal function of ANP replacement therapy during cardiopul-
onary bypass in 40 patients with normal renal function who
nderwent coronary-aorta bypass surgery. The 40 patients
ere randomly distributed between the ANP group and
he control group. In the ANP group, carperitide infusion
as begun just after cardiopulmonary bypass at a rate
f 0.025g/kg/min for 24 h, and GFR was calculated by
he serum creatinine level and urinary excretion of creati-
ine for 3 days. After cardiopulmonary bypass, GFR rapidly
ecreased to ∼70% level of the pre-operative level in the
ontrol group, but in the ANP group, GFR did not decrease
nd was maintained at a high level throughout the 3-
ay observation period, with concomitant favorable effects
ncluding larger urine volume, larger urinary excretion of
odium, and lower plasma aldosterone level compared with
he control group.
rotective effect of ANP on contrast-induced
ephropathyecently, renal-protective effect of ANP infusion was also
emonstrated in patients who underwent cardiac catheter-
zation. Contrast-induced nephropathy is one of the most
mportant clinical complications associated with coronary
igure 3 Infarct size (A) and ejection fraction (B) as primary
ndpoints in the J-WIND trial.
eproduced from Kitakaze et al. [47] with permission.
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bigure 4 Incidence of contrast-induced nephropathy (CIN).
eproduced from Morikawa et al. [49] with permission.
ngiography and enhancement of computed tomography.
ecently, Morikawa et al. [49] reported prevention of
ontrast-induced nephropathy by ANP infusion. They con-
ucted a prospective, randomized controlled trial in 254
onsecutive patients with serum creatinine concentration
igher than 1.3mg/dl: 126 patients were treated with
.042g/kg/min of carperitide plus 1.3ml/kg/h of Ringer
olution (ANP group), and 128 patients were treated with
inger solution alone (control group). Either treatment was
egun 4—6h prior to the catheterization and lasted for 48 h.
t baseline, there was no signiﬁcant difference between
he two groups in demographics including age, sex, blood
ressure, renal function, ejection fraction, and frequency of
rugs used. The prevalence of contrast-induced nephropa-
hy, deﬁned as a 25% increase or at least 0.5mg/dl of
ncrease in serum creatinine from baseline within 48 h,
as signiﬁcantly lower in the ANP group than in the con-
rol group (3.2% vs. 11.7%, p < 0.015). Serial changes in the
erum creatinine level, serum cystatin C level and esti-
ated GFR were compared between the two groups at
4 h, 48 h, 1 week, and 1 month after the procedures.
hese parameters for glomerular function slightly dete-
iorated in the control group but did not deteriorate in
he ANP group; there was a signiﬁcant difference in these
arameters between the groups. However, biomarkers for
ubular function, such as urinary 2-microglobulin and uri-
ary N-acetyl--D-glucosamidase (NAG), were similar in both
roups. The use of a volume of contrast medium >155ml
odds ratio: 6.89; p < 0.001), and ANP treatment (odds ratio:
.24; p < 0.016) were signiﬁcant predictors of developing
ontrast-induced nephropathy (Fig. 4).
omparison between carperitide and nesiritide
s mentioned above, because ANP and BNP bind the same
eceptor, GC-A, in order to stimulate biological effects,
he main therapeutic uses of ANP and BNP are similar.
owever, BNP has a lower afﬁnity for the clearance recep-
or and neutral endopeptidase, which degrades NPs and
radykinin, than ANP. Plasma half-lives of ANP and BNP
[[
[
[
[
[
[
[
[
[
[
[
[Roles of atrial natriuretic peptide and its therapeutic use
are 2.4± 0.7 and 12.1± 3.0min, respectively, in patients
with HF [50], which inﬂuence the dose of each peptide
used. In the case of ANP treatment, usually it begins at
a rate of 0.025—0.05g/kg/min, whereas BNP treatment
usually begins at a rate of 0.01g/kg/min following an ini-
tial 2g/kg of bolus injection. Furthermore, considering the
difference in half-life of these peptides, it is reasonable
to speculate that ANP more easily controls its effects and
adverse effects, such as hypotension, than BNP.
In 2005, Sackner-Bernstein et al. reported that the intra-
venous administration of nesiritide might increase the serum
creatinine level and the risk of short-term mortality (5).
Although this report had a strong impact here in Japan, some
cardiologists reacted with suspicion, because Japanese car-
diologists felt that carperitide had a beneﬁcial effect on
renal function. A recent meta-analysis reported in 2009,
showed that according to most of the trials presented, intra-
venous infusion of nesiritide in patients with ADHF neither
worsens their renal function nor increases their short-term
and long-term mortality (6). Furthermore, as mentioned
above, carperitide may have a renal-protective effect.
Acknowledgment
I thank Mari Miyagawa for her excellent secretarial work.
References
[1] de Bold AJ, Flynn TG. Cardionatrin I—–a novel heart pep-
tide with potent diuretic and natriuretic properties. Life Sci
1983;33:297—302.
[2] Kangawa K, Matsuo H. Puriﬁcation and complete amino acid
sequence of alpha-human atrial natriuretic polypeptide (alpha-
hANP). Biochem Biophys Res Commun 1984;118:131—9.
[3] Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and
biochemistry of the natriuretic peptide system. I: natriuretic
peptides. J Hypertens 1992;10:907—12.
[4] Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and
biochemistry of the natriuretic peptide system. II: natriuretic
peptide receptors. J Hypertens 1992;10:1111—4.
[5] Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of wors-
ening renal function with nesiritide in patients with acutely
decompensated heart failure. Circulation 2005;111:1487—91.
[6] Dontas ID, Xanthos T, Dontas I, Lelovas P, Papadimitriou
L. Impact of nesiritide on renal function and mortality in
patients suffering from heart failure. Cardiovasc Drugs Ther
2009;23:221—33.
[7] Mentzer Jr RM, Oz MC, Sladen RN, Graeve AH, Hebeler Jr RF,
Luber Jr JM, Smedira NG, NAPA Investigators. Effects of periop-
erative nesiritide in patients with left ventricular dysfunction
undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol
2007;49:716—26.
[8] Kisch B. Electron microscopy of the atrium of the heart. Exp
Med Surg 1956;14:99—112.
[9] de Bold AJ. Heart atria granularity effects of changes in water-
electrolyte balance. Proc Soc Exp Biol Med 1979;161:508—11.
[10] Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic
peptide in porcine brain. Nature 1988;332:78—81.
[11] Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic
peptide (CNP): a new member of natriuretic peptide fam-
ily identiﬁed in porcine brain. Biochem Biophys Res Commun
1990;168:863—70.
[12] Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda
K, Shirakami G, Suga S, Minamino N, Kangawa K, Matsuo H,
[269
Imura H. Brain natriuretic peptide is a novel cardiac hormone.
Biochem Biophys Res Commun 1989;158:360—8.
13] Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa
Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natri-
uretic peptide as a novel cardiac hormone in humans. Evidence
for an exquisite dual natriuretic peptide system, atrial natri-
uretic peptide and brain natriuretic peptide. J Clin Invest
1991;87:1402—12.
14] Ogawa Y, Nakao K, Mukoyama M, Shirakami G, Saito Y, Arai H,
Suga S, Jougasaki M, Itoh H, Hosoda K, Yamada T, Kambayashi
Y, Inouye K, Imura H. Rat brain natriuretic peptide-Tissue dis-
tribution and molecular form. Endocrinology 1990;126:2225—
7.
15] Hofmann F, Bernhard D, Lukowski R, Weinmeister P. cGMP reg-
ulated protein kinases (cGK): a textbook of cGMP: generators,
effectors and therapeutic implications. Verlag, Berlin, Heidel-
berg, Germany: Springer; 2009. pp. 137—162.
16] Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer
SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendel-
sohn ME. Regulator of G-protein signaling-2 mediates vascular
smooth muscle relaxation and blood pressure. Nat Med
2003;9:1506—12.
17] Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin
BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular
endothelium is critically involved in the hypotensive and hypo-
volemic actions of atrial natriuretic peptide. J Clin Invest
2005;115:1666—74.
18] Abassi ZA, Winaver J, Skorecki KL. Control of extracellular
ﬂuid volume and the pathophysiology of edema formation: a
textbook of disturbances in control of body ﬂuid volume and
composition. In: Brenner BM, editor. Brenner & Rector’s The
Kidney, vol. 1, 7th ed. Philadelphia, Saunders, USA: The Kidney;
1999. p. 777—855.
19] John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB,
Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial
natriuretic peptide and salt-sensitive hypertension. Science
1995;267:679—81.
20] Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen
J, Garbers DL, Beuve A. Salt-resistant hypertension in mice
lacking the guanylyl cyclase-A receptor for atrial natriuretic
peptide. Nature 1995;378:65—8.
21] Li Y, Saito Y, Kuwahara K, Rong X, Kishimoto I, Harada M,
Adachi Y, Nakanishi M, Kinoshita H, Horiuchi M, Murray M, Nakao
K. Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-
mediated pro-hypertrophic signaling in the heart. Circulation
2002;106:1722—8.
22] Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat
A, Begrow F, Schneider MD, Garbers DL, Kuhn M. Pressure-
independent cardiac hypertrophy in mice with cardiomyocyte-
restricted inactivation of the atrial natriuretic peptide
receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399—407.
23] Tokudome T, Kishimoto I, Horio T, Arai Y, Schwenke DO, Hino J,
Okano I, Kawano Y, Kohno M, Miyazato M, Nakao K, Kangawa K.
Regulator of G-protein signaling subtype 4 mediates antihyper-
trophic effect of locally secreted natriuretic peptides in the
heart. Circulation 2008;117:2329—39.
24] Zhang Q, Saito Y, Naya N, Imagawa K, Somekawa S, Kawata
H, Takeda Y, Uemura S, Kishimoto I, Nakao K. The speciﬁc
mineralocorticoid receptor blocker eplerenone attenuates left
ventricular remodeling in mice lacking the gene encoding
guanylyl cyclase-A. Hypertens Res 2008;31:1251—6.
25] Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast
R, Zetsche B, Hammer RE, Herz J, Kuhn M. Smooth muscle-
selective deletion of guanylyl cyclase-A prevents the acute but
not chronic effects of ANP on blood pressure. Proc Natl Acad
Sci USA 2002;99:7142—7.
26] Sabrane K, Kruse MN, Gazinski A, Kuhn M. Chronic endothelium-
dependent regulation of arterial blood pressure by atrial
2[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[70
natriuretic peptide: role of nitric oxide and endothelin-1.
Endocrinology 2009;150:2382—7.
27] Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Mat-
sumura T, Mukoyama M, Nakao K. Increased plasma levels of
brain natriuretic peptide in patients with acute myocardial
infarction. Circulation 1993;88:82—91.
28] Mizuno Y, Yasue H, Oshima S, Yoshimura M, Ogawa H, Morita E,
Saito T, Yamashita S, Noda K, Sumida H, Motoyama T, Soejima H,
Nakao K. Effects of angiotensin-converting enzyme inhibitor on
plasma B-type natriuretic peptide levels in patients with acute
myocardial infarction. J Card Fail 1997;3:287—93.
29] Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Taka-
hashi N, Kawakami R, Nakagawa Y, Tanimoto K, Yasuno S,
Usami S, Li Y, Adachi Y, Fukamizu A, Garbers DL, et al. Role
of natriuretic peptide receptor guanylyl cyclase-A in myocar-
dial infarction evaluated using genetically engineered mice.
Hypertension 2005;46:441—7.
30] Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka
I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H,
Garbers DL, Mochizuki S, Nakao K. Blockade of the natriuretic
peptide receptor guanylyl cyclase-A inhibits NF-kappaB activa-
tion and alleviates myocardial ischemia/reperfusion injury. J
Clin Invest 2001;108:203—13.
31] Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K,
Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami
S, Yasuno S, Kinoshita H, Chusho H, Tamura N, Ogawa Y,
et al. Overexpression of brain natriuretic peptide facilitates
neutrophil inﬁltration and cardiac matrix metalloproteinase-
9 expression after acute myocardial infarction. Circulation
2004;110:3306—12.
32] Kasahara M, Mukoyama M, Sugawara A, Makino H, Suganami T,
Ogawa Y, Nakagawa M, Yahata K, Goto M, Ishibashi R, Tamura
N, Tanaka I, Nakao K. Ameliorated glomerular injury in mice
overexpressing brain natriuretic peptide with renal ablation. J
Am Soc Nephrol 2000;11:1691—701.
33] Suganami T, Mukoyama M, Sugawara A, Mori K, Nagae T, Kasa-
hara M, Yahata K, Makino H, Fujinaga Y, Ogawa Y, Tanaka I,
Nakao K. Overexpression of brain natriuretic peptide in mice
ameliorates immune-mediated renal injury. J Am Soc Nephrol
2001;12:2652—63.
34] Makino H, Mukoyama M, Mori K, Suganami T, Kasahara M, Yahata
K, Nagae T, Yokoi H, Sawai K, Ogawa Y, Suga S, Yoshimasa Y,
Sugawara A, Tanaka I, Nakao K. Transgenic overexpression of
brain natriuretic peptide prevents the progression of diabetic
nephropathy in mice. Diabetologia 2006;49:2514—24.
35] Tokudome T, Kishimoto I, Yamahara K, Osaki T, Minamino N,
Horio T, Sawai K, Kawano Y, Miyazato M, Sata M, Kohno M, Nakao
K, Kangawa K. Impaired recovery of blood ﬂow after hind-
limb ischemia in mice lacking guanylyl cyclase-A, a receptor
for atrial and brain natriuretic peptides. Arterioscler Thromb
Vasc Biol 2009;29:1516—21.
36] Kuhn M, Völker K, Schwarz K, Carbajo-Lozoya J, Flögel U,
Jacoby C, Stypmann J, van Eickels M, Gambaryan S, Hart-
mann M, Werner M, Wieland T, Schrader J, Baba HA. The
natriuretic peptide/guanylyl cyclase—–a system functions as
a stress-responsive regulator of angiogenesis in mice. J Clin
Invest 2009;119:2019—30.
37] Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N,
Fukunaga Y, Sone M, Yurugi-Kobayashi T, Miyashita K, Tsujimoto
H, Kook H, Feil R, Garbers DL, Hofmann F, et al. Signiﬁcance and
therapeutic potential of the natriuretic peptides/cGMP/cGMP-
dependent protein kinase pathway in vascular regeneration.
Proc Natl Acad Sci USA 2003;100:3404—9.
[Y. Saito
38] Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata
K, Sonoda R, Ban T, Yasue H, Imura H. Clinical application of
atrial natriuretic polypeptide in patients with congestive heart
failure: beneﬁcial effects on left ventricular function. Circula-
tion 1987;76:115—24.
39] Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman
KS, Shaknovich A, Pondolﬁno K, Clark M, Camargo MJ.
Atrial natriuretic factor in normal subjects and heart failure
patients. Plasma levels and renal, hormonal, and hemodynamic
responses to peptide infusion. J Clin Invest 1986;78:1362—74.
40] Crozier IG, Nicholls MG, Ikram H, Espiner EA, Gomez HJ, Warner
NJ. Haemodynamic effects of atrial peptide infusion in heart
failure. Lancet 1986;2:1242—5.
41] Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter
prospective investigation on efﬁcacy and safety of carperitide
for acute heart failure in the ‘real world’ of therapy. Circ J
2005;69:283—90.
42] Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani
Y. Multicenter prospective investigation on efﬁcacy and safety
of carperitide as a ﬁrst-line drug for acute heart failure syn-
drome with preserved blood pressure: COMPASS: carperitide
effects observed through monitoring dyspnea in acute decom-
pensated heart failure study. Circ J 2008;72:1777—86.
43] Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa
T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita
M. Effects of carperitide on the long-term prognosis of
patients with acute decompensated chronic heart failure:
the PROTECT multicenter randomized controlled study. Circ J
2008;72:1787—93.
44] Ishikawa C, Tsutamoto T, Wada A, Fujii M, Ohno K, Sakai H,
Yamamoto T, Horie M. Inhibition of aldosterone and endothelin-
1 by carperitide was attenuated with more than 1 week of
infusion in patients with congestive heart failure. J Cardiovasc
Pharmacol 2005;46:513—8.
45] Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K,
Suzuki S, Mizuno Y, Sugiyama S, Saito Y, Nakao K, Yasue H,
Ogawa H. Predominant effect of A-type natriuretic peptide on
reduction of oxidative stress during the treatment of patients
with heart failure. Circ J 2007;71:1040—6.
46] Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T,
Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic
peptide prevents left ventricular remodeling in patients with
ﬁrst anterior acute myocardial infarction. J Am Coll Cardiol
2001;37:1820—6.
47] Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki
T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto
S, Watanabe K, Fukuzawa S, Hirayama A, et al. Human atrial
natriuretic peptide and nicorandil as adjuncts to reperfusion
treatment for acute myocardial infarction (J-WIND): two ran-
domised trials. Lancet 2007;370:1483—93.
48] Sezai A, Shiono M, Orime Y, Hata H, Hata M, Negishi N, Sezai
Y. Low-dose continuous infusion of human atrial natriuretic
peptide during and after cardiac surgery. Ann Thorac Surg
2000;69:732—8.
49] Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi
M, Morita Y, Numaguchi Y, Okumura K, Murohara T. Renal
protective effects and the prevention of contrast-induced
nephropathy by atrial natriuretic peptide. J Am Coll Cardiol
2009;53:1040—6.
50] Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H,
Uemura S, Saito Y. ANP is cleared much faster than BNP in
patients with congestive heart failure. Eur J Clin Pharmacol
2007;63:699—702.
